Celanese Exhibits Safe, Reliable, Compliant Medical Polymers At K 2016, World’s Largest Plastics Fair

DALLAS & DÜSSELDORF, Germany--(BUSINESS WIRE)--When treating patients, precision and performance are critical to medical device usage and drug dispensing. Celanese Corporation (NYSE: CE), a global technology and specialty materials company, will highlight polymers that help manufacturers of medical devices – from surgical tools to orthopedic implants – improve product design, safety and effectiveness at the K 2016 plastics show in Düsseldorf, Germany as the company showcases the Art of Material Selection.

“As medical materials are pushed to perform at higher levels, manufacturers are looking to certified medical-grade polymers to conform to specific property and quality standards, as well as applicable regulatory requirements”

“As medical materials are pushed to perform at higher levels, manufacturers are looking to certified medical-grade polymers to conform to specific property and quality standards, as well as applicable regulatory requirements,” said Todd Elliott, vice president of Material Solutions, Celanese. “At K 2016, we will show our customers the value of partnering with Celanese as they face the challenges of selecting medical-grade materials.”

Medical device researchers and manufacturers use Celanese MT® (Medical Technology) grade polymers to design products capable of moving parts, precision dosing and wear resistance. Devices such as orthopedic implants last longer and are more life-like when made with these polymers. Insulin injection pens and measured drug delivery devices, such as syringes and asthma inhalers, are made stronger with MT® grade polymers that are durable, reliable and compliant. Celanese polymers are tested to have the required medical properties for consistent operation critical to patients and practitioners.

Isaac Khalil, Celanese vice president of Global Medical, stated: “Celanese is continuing to expand its MT® portfolio to meet our customers’ increasing requirements. Customer design trends that are critical to quality include connectivity, miniaturization, aesthetics and part precision. Celanese’s medical portfolio is catering to these trends, with solutions such as laser-direct structuring, high flow Vectra® LCP, molded-in-color polymers, heat dissipating technology, USP Class VI standards, and DMF access and regulatory support.”

At K 2016, Celanese will highlight three strategies to successful product development and manufacturing using its MT® grade engineered materials:

• Design Freedom: The Celanese portfolio of medical grade polymers helps keep medical devices easy to operate, enables efficient and safe treatment administration, and ensures ease-of-use for patients, thereby allowing manufacturers to bring new products to market faster with greater user acceptance.
• Appearance: Medical devices are complex and so are the requirements to differentiate and identify critical components. The Celanese MT® product portfolio helps designers address these challenges with highly tested, low-wear materials that allow for molding in the shapes and forms needed for each component. Patients with chronic conditions depend on these devices to have a discrete look and size, carefully choosing the ones that work best.
• Performance: The extreme properties and quality standards of Celanese medical-grade polymers – such as the Ateva^® G-series ethylene vinyl acetate polymers used in blood bags, nutrition bags and medical tubing – help manufacturers design and make devices that are high performing, durable and operate consistently, all critical to treatment compliance, patient health and quality of life.

Decades of polymer development, technical expertise and life sciences industry knowledge goes into each Celanese medical-grade material. The Celanese MT^® and Ateva^® G-series medical polymers address many of today’s challenges such as patient compliance and dosage frequency to offer proven, safe and reliable materials.

Celanese engineers work closely with medical device researchers and manufacturers around the world to interpret their critical requirements and identify the right polymers from the broad portfolio of material solutions that meet regulatory requirements. They also guide designs to be effective, functional and accurate while streamlining development and regulatory approvals.

Celanese continues to support customer franchises in diabetes care, COPD and orthopedics with a broad and expanding materials portfolio. Customers can utilize Celanese’s MT® service package for consistently high quality materials, continuity of supply and technical support.

To learn more about Celanese engineered materials for the medical industry and the Art of Material Selection, explore the Celanese booth at K 2016 in Hall 6 stand #6A07.

To learn more about K 2016, visit www.k-online.com/.

About Celanese

Celanese Corporation is a global technology leader in the production of differentiated chemistry solutions and specialty materials used in most major industries and consumer applications. Our two complementary business cores, Acetyl Chain and Materials Solutions, use the full breadth of Celanese’s global chemistry, technology and business expertise to create value for our customers and the corporation. As we partner with our customers to solve their most critical business needs, we strive to make a positive impact on our communities and the world through The Celanese Foundation. Based in Dallas, Celanese employs approximately 7,000 employees worldwide and had 2015 net sales of $5.7 billion. For more information about Celanese and our product offerings, visit www.celanese.com or our blog at www.celaneseblog.com.

All registered trademarks are owned by Celanese International Corporation or its affiliates.

Forward-Looking Statements

This release may contain “forward-looking statements,” which include information concerning the company’s plans, objectives, goals, strategies, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. When used in this release, the words “outlook,” “forecast,” “estimates,” “expects,” “anticipates,” “projects,” “plans,” “intends,” “believes,” and variations of such words or similar expressions are intended to identify forward-looking statements. All forward-looking statements are based upon current expectations and beliefs and various assumptions. There can be no assurance that the company or its customers will realize these benefits or that these expectations will prove correct. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements contained in this release. Numerous factors, many of which are beyond the company’s control, could cause actual results to differ materially from those expressed as forward-looking statements. Other risk factors include those that are discussed in the company’s filings with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it is made, and the company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances.